Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares RepurchasedShort-Term Debt repayments
Ratios

Ani Pharmaceuticals (ANIP) Accumulated Depreciation & Amortization (2016 - 2025)

Ani Pharmaceuticals' Accumulated Depreciation & Amortization history spans 15 years, with the latest figure at $91.4 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 34.97% year-over-year to $91.4 million; the TTM value through Dec 2025 reached $91.4 million, up 34.97%, while the annual FY2025 figure was $91.4 million, 34.97% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $91.4 million at Ani Pharmaceuticals, up from $67.7 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $91.4 million in Q4 2025 and bottomed at $18.8 million in Q1 2021.
  • The 5-year median for Accumulated Depreciation & Amortization is $27.3 million (2022), against an average of $39.0 million.
  • The largest annual shift saw Accumulated Depreciation & Amortization skyrocketed 148.18% in 2022 before it rose 4.95% in 2023.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $23.0 million in 2021, then surged by 148.18% to $57.0 million in 2022, then increased by 4.95% to $59.8 million in 2023, then grew by 13.28% to $67.7 million in 2024, then surged by 34.97% to $91.4 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Accumulated Depreciation & Amortization are $91.4 million (Q4 2025), $67.7 million (Q4 2024), and $59.8 million (Q4 2023).